Skip to main content

Advertisement

Table 1 The clinico-pathologic characteristics of the study population

From: Skin-sparing mastectomy and immediate latissimus dorsi flap reconstruction: a retrospective analysis of the surgical and patient-reported outcomes

  Group 1 (n = 39) Group 2 (n = 26) P-value
  mean±SD (range)/n (%) mean±SD (range)/n (%)  
Age, years 49.64 ± 10.6 (21to 74) 46.6 ± 7.7 (33 to 64) 0.209
Follow-up, months 36.5 ± 26.3 (1.6 to 89.9) 30.4 ± 21.9 (1.6 to 84.1) 0.333
Pathology    0.446
 Infiltrating ductal carcinoma 29 (74.4) 19 (73.1)  
 Ductal carcinoma in situ 8 (20.5) 7 (26.9)  
 Infiltrating lobular carcinoma 2 (5.1) 0  
Tumor size, cm 2.1 ± 0.9 (0.2 to 4.8) 1.8 ± 0.9 (0.2 to 3.5) 0.304
Stage    0.274
 0 8 (20.5) 7 (26.9)  
 I 16 (41.0) 13 (50.0)  
 IIA 10 (25.6) 3 (11.5)  
 IIB 4 (10.3) 3 (11.5)  
 IIIA 1 (2.6) 0  
T    0.493
 Tis 8 (20.5) 7 (26.9)  
 T1 17 (43.6) 13 (50.0)  
 T2 14 (35.9) 6 (23.1)  
N    0.489
 N0 32 (82.0) 23 (88.5)  
 N1 6 (15.4) 3 (11.5)  
 N2 1 (2.6) 0  
Adjuvant chemotherapy    0.441
 No 18 (46.2) 18 (69.2)  
 CMFa 12 (30.8) 4 (15.4)  
 AC-Tb 3 (7.7) 1 (3.8)  
TACc 3 (7.7) 2 (7.7)  
FACd 3 (7.7) 1 (3.8)  
Anti-hormone therapy    0.548
 No 8 (20.5) 7 (26.9)  
 Yes 31 (79.5) 19 (73.1)  
Radiotherapy    0.411
 No 38 (97.4) 26 (100)  
 Yes 1 (2.6) 0  
Local recurrence    
 No 39 (100) 26 (100)  
 Yes 0 0  
Regional Metastasis    0.411
 No 38 (97.4) 26 (100)  
 Yes 1 (2.6) 0  
  1. aCMF:cyclophosphamide, methotraxate, flurouracil; bA, doxorubicin; C, cyclophosphamide; T, docetaxel; cT, docetaxel, A, doxorubicin, C, cyclophosphamide; dFAC: flurouracil, epirubicin, cyclophosphamide.